AustinPx logo — Client-Centric CDMO helping developers realize the full pote...

AustinPx

Client-Centric CDMO helping developers realize the full potential of their drug candidates.

Founded 2007 United States Georgetown, United States 44 employees Venture round Total: $57.97M Manufacturing, Pharmaceutical

General Information

Company Name AustinPx
Founded Year 2007
Location United States Georgetown, United States
Employees 44
Industries Manufacturing, Pharmaceutical
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with AustinPx. To contact AustinPx, visit austinpx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About AustinPx

AustinPx™ is a Client-Centric CDMO founded in 2007 with the slogan "Client-Centric CDMO helping developers realize the full potential of their drug candidates." This company operates in the Manufacturing and Pharmaceutical industries, with its headquarters in the United States. In 16 October 2020, the company secured a significant $4.69M venture round investment. AustinPx™ aims to assist developers in overcoming obstacles hindering the successful introduction of their drug candidates to the market. The company's proprietary KinetiSol™ Technology – a next-generation amorphous solid dispersion (ASD) technology for poorly soluble APIs – aims to disrupt the ASD industry. This technology offers a smaller footprint, a broader design space, and a greener processing solution. AustinPx™'s client-centric approach simplifies the complexity of outsourcing, and its team of formulation, analytical, and manufacturing experts collaborates with clients to expedite processes and capitalize on opportunities for accelerated development.

Taxonomy: CDMO, Pharmaceutics, Drug development, Bioavailability, Formulation, Analytical services, KinetiSol™ Technology, Amorphous solid dispersions, Solubility enhancement, Oral Dose Forms, Client-centric, DisperSol Technologies, Edward M. Rudnic, Innovation

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $4.69M -
16 Oct 2020
Venture Round $27.00M 2
RCT, Acadia Woods Partners
26 Apr 2018
Venture Round $12.00M -
02 Feb 2016
Venture Round $10.00M 1
RCT
03 Feb 2015
Venture Round $3.02M -
10 Mar 2014
Debt Financing $611.83K -
29 May 2013
Venture Round $641.69K -
24 Jan 2012

AustinPx Alternatives & Competitors

AustinPx vs
Catalent
Catalent United States

more products. better treatments. reliably supplied. ™

Post-IPO Debt
12614 employees
Biotechnology, Manufacturing
AustinPx vs
Delpharm
Delpharm France

A worldwide leader in contract development and manufacturing of medicines

Late Stage
3905 employees
Health Care, Manufacturing
AustinPx vs
Ofichem Group
Ofichem Group The Netherlands

Family-owned CDMO and pharmaceutical supplier

54 employees
Manufacturing, Pharmaceutical

FAQ About AustinPx

Client-Centric CDMO helping developers realize the full potential of their drug candidates.
AustinPx was founded in 2007.
AustinPx is headquartered in Georgetown, United States.
AustinPx operates in Manufacturing and Pharmaceutical. Its work centres on CDMO, Pharmaceutics, Drug development and Bioavailability.
AustinPx has approximately 44 employees.
AustinPx has completed 7 funding rounds, raising a total of $57.97M. The latest funding stage is Venture round.
Top alternatives and competitors to AustinPx include Catalent, Delpharm, Ofichem Group, LTS Lohmann Therapie-Systeme AG, Mikart, LLC. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AustinPx and Catalent are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for AustinPx, https://bouncewatch.com/company/austinpx, updated 6 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes